Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01661855
Other study ID # RILISE-07-2013
Secondary ID
Status Completed
Phase Phase 2
First received July 26, 2012
Last updated March 17, 2017
Start date September 2013
Est. completion date October 2015

Study information

Verified date March 2017
Source Anagnostou, Evdokia, M.D.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will examine the potential efficacy and safety of riluzole for core and associated symptom domains of autism and will explore biological markers of safety and treatment response.


Description:

There are no pharmacologic treatments available for social function deficits in individuals with Autism Spectrum Disorders (ASD). The data for pharmacologic treatment of repetitive behaviors in this disorder has also become difficult to interpret given that the last two large multisite trials of selective serotonin reuptake inhibitors (SSRIs) in autism are reported to be negative for the treatment of repetitive behaviors. Only the associated symptom of irritability has 2 drugs with FDA indications whereas no systematic data exists on the pharmacologic treatment of anxiety in ASD, and response to rates to stimulants for hyperactivity are lower than what is seen in attention deficit hyperactivity disorder (ADHD). In addition, there are no biological markers of treatment response identified in this population at this point. This study will examine the potential efficacy and safety of riluzole for core and associated symptom domains of autism and will explore biological markers of safety and treatment response.


Recruitment information / eligibility

Status Completed
Enrollment 58
Est. completion date October 2015
Est. primary completion date September 2015
Accepts healthy volunteers No
Gender All
Age group 6 Years to 17 Years
Eligibility Inclusion Criteria:

1. Male or female outpatients 6-17 years of age inclusive, with a mental age equivalent = 18 months at Screening visit.

2. Meet Diagnostic and Statistical Manual (DSM-IV) criteria for an ASD.

3. Have a Clinician's Global Impression-Severity (CGI-S) score = 4 (moderately ill) at Screening.

4. If already receiving stable interventions must meet the following criteria:

1. If already receiving stable concomitant medications affecting behavior, must be on a stable dose during the preceding 1 month prior to Screening (with the exception of fluoxetine, where a period of 6 weeks is needed), and will not electively initiate new or modify ongoing medications for study duration.

2. If already receiving stable non-pharmacological educational, behavioral, and/or dietary interventions, have continuous participation during the preceding 3 months prior to Screening, and not electively initiate new or modify ongoing interventions for the duration of the study.

5. Have normal physical examination and laboratory test results at Screening. If abnormal, the finding(s) must be deemed clinically insignificant by the Investigator.

6. Ability to complete assessments- fluency in English (parent; patient, if verbal).

7. Consent to participate in the Province of Ontario Neurodevelopmental (POND) study and commitment to completing as many stages as possible of the phenotyping measures (Stages 1, 2 and 3), genomics component, and interest in being imaged through POND.

8. Ability to obtain written informed consent from the participant, if developmentally appropriate. If a participant does not have the capacity to consent, ability to obtain assent (if developmentally appropriate), as well as written informed consent from their parent(s)/legal guardian.

Exclusion Criteria:

1. Pregnant female patients; sexually active female patients on inadequate birth control.

2. Patients with a serious medical condition that, based on Investigator judgment, might interfere with the conduct of the study, confound interpretation of the study results, or endanger their own well-being. Patients with evidence or history of malignancy or any significant hematological, endocrine, cardiovascular (including any rhythm disorder), respiratory, renal, hepatic, or gastrointestinal disease, not including mild common pediatric diseases in these areas that are stable (e.g. mild asthma, constipation, etc.).

3. Patients with unstable epilepsy (i.e. seizures occurring within the last 6 months), or patients with epilepsy who are not on stable doses of antiepileptic medications (i.e. dose changes within the last 3 months).

4. Patients with hypersensitivity to riluzole or any components of its formulation.

5. Patients with one or more of the following: HIV, Hepatitis B virus, Hepatitis C virus, hemophilia (bleeding problems, recent nose and brain injuries), abnormal blood pressure (hypotension or hypertension), drug abuse, immunity disorder, major depressive episode or psychosis.

6. Patients unable to tolerate venipuncture procedures for blood sampling.

7. Patients receiving concomitant medications that specifically target the glutamate system (e.g. memantine, d-cycloserine), or decrease the elimination of riluzole (e.g. theophylline, quinolones), less than 30 days prior to the screening visit.

8. Patients actively enrolled in another intervention study.

9. Patients who are unable to swallow pills.

10. Patients who have elevated liver enzymes = 3 times the normal amount before the study begins.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Riluzole
50mg once daily (QD) for 12 weeks for participants 6-11 years old; 50mg twice daily (BID) for 12 weeks for participants 12-17 years old
Placebo
Placebo comparator once daily (QD) for 12 weeks for participants 6-11 years old; Placebo comparator twice daily (BID) for 12 weeks for participants 12-17 years old

Locations

Country Name City State
Canada Offord Centre for Child Studies Hamilton Ontario
Canada Lawson Health Research Institute London Ontario
Canada Holland Bloorview Kids Rehabilitation Hospital Toronto Ontario

Sponsors (7)

Lead Sponsor Collaborator
Evdokia Anagnostou Holland Bloorview Kids Rehabilitation Hospital, McMaster University, St. Michael's Hospital, Toronto, The Hospital for Sick Children, University of Toronto, University of Western Ontario, Canada

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy of riluzole vs. placebo on measures of social function This will be measured by the Aberrant Behavior Checklist (ABC) - Lethargy / Social Withdrawal Subscale 12 weeks
Primary Efficacy of riluzole vs. placebo on measures of repetitive behaviors This will be measured by the Child Yale-Brown Obsessive Compulsive Scale (CY-BOCS) 12 weeks
Primary Efficacy of riluzole vs. placebo on measures of repetitive behaviors This will be measured by the Repetitive Behavior Scale (RBS-R) 12 weeks
Primary Safety and tolerability of riluzole in children and adolescents with ASD This will be measured by the Safety Monitoring Uniform Report Form (SMURF) 12 Weeks
Primary Safety and tolerability of riluzole in children and adolescents with ASD This will be measured by the Clinical Global Impressions - Improvement Scale - Global (CGI-I-Global) 12 Weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02625116 - ELENA Cohort: A Long-term Longitudinal Study in a Pediatric Sample With Autism Spectrum Disorders
Not yet recruiting NCT06381856 - Improving Participation of Autistic Children and Adolescents in the Habilitation Process
Recruiting NCT02280746 - Gluten for Autism Spectrum Disorders N/A
Completed NCT01945957 - Brain Imaging of Intranasal Oxytocin Treatment in Autism Phase 1
Completed NCT01592747 - Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine Phase 2
Completed NCT01780090 - Handheld Technology for Speech Development in Students With Autism N/A
Completed NCT01694667 - Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder Phase 2
Completed NCT01691066 - Pivotal Response Treatment for Infants At-Risk for Autism Spectrum Disorder N/A
Active, not recruiting NCT01417026 - Intranasal Oxytocin and Learning in Autism Phase 2
Enrolling by invitation NCT01364818 - Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment N/A
Completed NCT01695200 - Omega-3 Fatty Acids in Autism Spectrum Disorders Phase 4
Completed NCT02300597 - Internet-based Support for Young People With ADHD and Autism - a Controlled Study N/A
Completed NCT01675414 - Understanding Gastrointestinal Conditions in Children With Autism Spectrum Disorder (ASD) N/A
Not yet recruiting NCT00695812 - The Development of Younger Siblings of Children With Autism Now at 10 Years of Age N/A
Recruiting NCT05910502 - Project AFECT (Autism Family Empowerment Coaching and Training Program) N/A
Completed NCT02081027 - Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders Early Phase 1
Completed NCT02797379 - The Development of a Psychoeducational Tool to Manage Anxiety in People With Autism Spectrum Disorders N/A
Terminated NCT01730079 - Near Infrared Spectroscopy in Children With Autism and ADHD
Completed NCT01603225 - Transcranial Direct Current Stimulation and Autism
Completed NCT01931033 - An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders N/A